Patents Assigned to AICHI MEDICAL UNIVERSITY
  • Publication number: 20210195887
    Abstract: The present invention provides a composition that can preserve biomaterials. The biomaterial preservation composition of the present invention includes a microbubble.
    Type: Application
    Filed: May 31, 2019
    Publication date: July 1, 2021
    Applicants: Aichi Medical University, Sumitomo Seika Chemicals Co., Ltd.
    Inventors: Naoyuki Hatayama, Munekazu Naito, Shuichi Hirai, Shigeki Sakaue
  • Patent number: 11028390
    Abstract: The present invention provides a suppression type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in any of SEQ ID NOs: 2-4, and a promotion type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in SEQ ID NO: 5.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: June 8, 2021
    Assignees: Osaka University, KNC Laboratories Co., Ltd., Aichi Medical University
    Inventors: Yoshitaka Nagai, Kazuhiro Maeta, Toshihide Takeuchi, Masahiro Neya, Tsuyoshi Fujihara, Seiji Matsuda, Gen Sobue, Shinsuke Ishigaki, Kentaro Sahashi
  • Publication number: 20210137098
    Abstract: The present invention provides a composition that can preserve cells. The composition of the present invention includes a microbubble.
    Type: Application
    Filed: May 31, 2019
    Publication date: May 13, 2021
    Applicants: Aichi Medical University, Sumitomo Seika Chemicals Co., Ltd.
    Inventors: Naoyuki Hatayama, Munekazu Naito, Shuichi Hirai, Kaori Fukushige, Shigeki Sakaue
  • Publication number: 20210102214
    Abstract: The present invention provides an antisense oligonucleotide for inhibiting biosynthesis of chondroitin sulfate. The antisense oligonucleotide comprises at least one modified nucleotide, wherein the antisense oligonucleotide suppresses expression of one or both of the chondroitin sulfate N-acetylgalactosaminyltransferase-1 (CSGalNAcT1) gene and the chondroitin sulfate N-acetylgalactosaminyltransferase-2 (CSGalNAcT2) gene.
    Type: Application
    Filed: February 20, 2018
    Publication date: April 8, 2021
    Applicant: Aichi Medical University
    Inventors: Satoshi OBIKA, Yuya KASAHARA, Kosei TAKEUCHI
  • Patent number: 9638697
    Abstract: It is an object of the present invention to provide a monoclonal antibody, which is suitable for the quantitative analysis of asparagine synthetase in a cell. The present invention provides a monoclonal antibody which specifically recognizes asparagine synthetase that is present in a cell.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: May 2, 2017
    Assignees: THE UNIVERSITY OF TOKYO, INSTITUTE OF IMMUNOLOGY CO., LTD., AICHI MEDICAL UNIVERSITY
    Inventors: Takao Hamakubo, Yasuhiro Mochizuki, Hiroko Iwanari, Osamu Arai, Toshiyuki Kitoh, Masahito Tsurusawa